About this Research Topic
The COVID-19 pandemic has had a significant impact on mental health worldwide, with many people experiencing anxiety, depression, and other mental health conditions. Psychotropic medications are commonly used to manage these conditions, and there is a need to examine the impact of COVID-19 on the use and efficacy of these substances.
This Research Topic aims to provide a comprehensive overview of the current evidence on the relationship between COVID-19 and use of psychotropic substances to manage COVID-19. We hope that it will inform clinical practice and help identify future research directions to optimize the use of psychotropic medication in the context of the COVID-19 pandemic. We welcome original research, review articles, and meta-analyses on themes including, but not limited to:
• the impact of the COVID-19 pandemic on the prescription and use of psychotropic medications/substances
• the effectiveness of psychotropic medication in managing mental health conditions during the COVID-19 pandemic
• the potential impact of COVID-19 on the pharmacokinetics and pharmacodynamics of psychotropic medications
• the impact of COVID-19 on patients with pre-existing mental health conditions who are taking psychotropic medications
• the use of psychotropic medication in the treatment of COVID-19 patients who experience psychiatric symptoms.
• the impact of COVID-19 on the mental health of healthcare workers who are taking psychotropic medications
• the impact of COVID-19 on the availability and accessibility of psychotropic medications
• the role of telepsychiatry in the prescription and management of psychotropic medications during the COVID-19 pandemic.
All submissions will undergo a rigorous peer-review process, and the final selection of articles will be based on their scientific quality, originality, and relevance to the scope of this Research Topic.
This Research Topic aims to provide a comprehensive overview of the current evidence on the relationship between COVID-19 and use of psychotropic substances to manage COVID-19. We hope that it will inform clinical practice and help identify future research directions to optimize the use of psychotropic medication in the context of the COVID-19 pandemic. We welcome original research, review articles, and meta-analyses on themes including, but not limited to:
• the impact of the COVID-19 pandemic on the prescription and use of psychotropic medications/substances
• the effectiveness of psychotropic medication in managing mental health conditions during the COVID-19 pandemic
• the potential impact of COVID-19 on the pharmacokinetics and pharmacodynamics of psychotropic medications
• the impact of COVID-19 on patients with pre-existing mental health conditions who are taking psychotropic medications
• the use of psychotropic medication in the treatment of COVID-19 patients who experience psychiatric symptoms.
• the impact of COVID-19 on the mental health of healthcare workers who are taking psychotropic medications
• the impact of COVID-19 on the availability and accessibility of psychotropic medications
• the role of telepsychiatry in the prescription and management of psychotropic medications during the COVID-19 pandemic.
All submissions will undergo a rigorous peer-review process, and the final selection of articles will be based on their scientific quality, originality, and relevance to the scope of this Research Topic.
Keywords: COVID, psychotropic medication, anxiety, depression
Important Note: All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.
